Severity: Warning
Message: file_get_contents(https://...@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
Filename: helpers/my_audit_helper.php
Line Number: 176
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 176
Function: file_get_contents
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 250
Function: simplexml_load_file_from_url
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3122
Function: getPubMedXML
File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global
File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword
File: /var/www/html/index.php
Line: 316
Function: require_once
This pilot project was performed to investigate the possible application of a portable CPAP helmet (continuous positive airway pressure) to treat high altitude diseases. Arterial oxygen saturation increased from 80.6 +/- 3.4 % to 90.6 +/- 3.8 % (p < 0.01, n = 14) when using the CPAP helmet (PEEP (positive endexpiratory pressure): 10-15 cm H2O) in normobaric hypoxia (FiO2 12.9 +/- 0.4 %, corresponding to about 4300 m). Furthermore arterial oxygen saturation was enhanced (88.1 +/- 1.9 % to 93.5 +/- 3.0 %; p < 0.01, n = 11) at real altitude (3150 m) after a 20 minute application of the CPAP helmet. There was a correlation between differences in PaCO2 and arterial oxygen saturation during CPAP (R = -0.97, p < 0.01, n = 6). Further studies are needed to determine the effectiveness, its mechanisms in context with altitude diseases, and the applicability of this treatment under extreme environmental conditions.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s10354-007-0502-y | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!